Search research articles
Contact Us
Filters
Showing results (121-130 of 174) with videos related to
Page
of 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 26, 2010
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer
Daniel J Sargent, Silvia Marsoni, Genevieve Monges, et al.
Clinical Colorectal Cancer
|
August 25, 2021
Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study
Eleonora Lai, Marco Puzzoni, Pina Ziranu, et al.
The Lancet. Oncology
|
December 3, 2020
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials
Thierry André, Jeffrey Meyerhardt, Timothy Iveson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2010
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study
Giuseppe Colucci, Roberto Labianca, Francesco Di Costanzo, et al.
Cancers
|
August 28, 2025
Baseline Hemostatic Biomarker Assessment Identifies Breast Cancer Patients at High Risk for Venous Thromboembolism During Chemotherapy
Marina Marchetti, Patricia Gomez-Rosas, Laura Russo, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
March 30, 2022
A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial
Gerardo Rosati, Chiara Alessandra Cella, Luigi Cavanna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2018
FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial
Alberto Sobrero, Sara Lonardi, Gerardo Rosati, et al.
Cancers
|
September 23, 2022
Thrombin Generation and D-Dimer for Prediction of Disease Progression and Mortality in Patients with Metastatic Gastrointestinal Cancer
Cinzia Giaccherini, Cristina Verzeroli, Laura Russo, et al.
Scientific Reports
|
November 18, 2015
Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)
Monica Ganzinelli, Eliana Rulli, Elisa Caiola, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 2009
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3
Eric Van Cutsem, Roberto Labianca, György Bodoky, et al.
Page
of 18
Search research articles
Search
Showing results (121-130 of 174) with videos related to
Sort By:
Page
of 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 26, 2010
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer
Daniel J Sargent, Silvia Marsoni, Genevieve Monges, et al.
Clinical Colorectal Cancer
|
August 25, 2021
Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study
Eleonora Lai, Marco Puzzoni, Pina Ziranu, et al.
The Lancet. Oncology
|
December 3, 2020
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials
Thierry André, Jeffrey Meyerhardt, Timothy Iveson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2010
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study
Giuseppe Colucci, Roberto Labianca, Francesco Di Costanzo, et al.
Cancers
|
August 28, 2025
Baseline Hemostatic Biomarker Assessment Identifies Breast Cancer Patients at High Risk for Venous Thromboembolism During Chemotherapy
Marina Marchetti, Patricia Gomez-Rosas, Laura Russo, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
March 30, 2022
A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial
Gerardo Rosati, Chiara Alessandra Cella, Luigi Cavanna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2018
FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial
Alberto Sobrero, Sara Lonardi, Gerardo Rosati, et al.
Cancers
|
September 23, 2022
Thrombin Generation and D-Dimer for Prediction of Disease Progression and Mortality in Patients with Metastatic Gastrointestinal Cancer
Cinzia Giaccherini, Cristina Verzeroli, Laura Russo, et al.
Scientific Reports
|
November 18, 2015
Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)
Monica Ganzinelli, Eliana Rulli, Elisa Caiola, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 2009
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3
Eric Van Cutsem, Roberto Labianca, György Bodoky, et al.
Page
of 18